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02 The Journal of Thoracic and Cardiobjectives: The purpose of this multi-institutional study was to review the 15-year
utcome of patients who received isolated aortic or mitral valve replacement with
he Hancock II bioprosthesis.
ethods: From 1983 through 2002, 1274 patients underwent 1293 isolated valve
eplacements, 809 aortic valve replacements and 484 mitral valve replacements, at
ospitals in the Venetian area (Padova, Treviso, and Venice). Mean age was 68 
years in patients undergoing aortic valve replacement and 66 9 years in patients
ndergoing mitral valve replacement; 52% of patients undergoing aortic valve
eplacement and 63% of patients undergoing mitral valve replacement were in New
ork Heart Association class III or greater. Coronary artery disease was present in
2% of patients who had undergone aortic valve replacement and 18% of patients
ho had undergone mitral valve replacement. Follow-up included 8520 patient-
ears, with a median of 12 years, and was 97% complete.
esults: Overall 15-year survival was 39.7%  2.4%, similar in both the aortic and
itral positions. Multivariable analysis of late survival showed the incremental risk of
ale sex, higher New York Heart Association class, coronary artery disease, and mitral
osition. Freedom from embolism was higher in the aortic position (81%  2.9% in
ortic vs 72%  4.7% in mitral valve replacements). Freedom from endocarditis was
imilar in the aortic and mitral position (95% 1.2% vs 94% 1.7%). Freedom from
eoperation (82% 3.7% vs 71% 5.0%) and from valve-related morbidity-mortality
52%  3.6% vs 36%  4.4%) was higher in patients who had undergone AVR.
ctual freedom from structural valve deterioration for patients 60 years and older
ho had undergone aortic valve replacement was 96.5%  1.3% versus 88% 
.2% for patients who had undergone mitral valve replacement and 70%  7.5%
ersus 77.5%  5.3%, respectively, in younger patients. Multivariable Weibull
nalysis showed structural valve deterioration related to younger age and preoper-
tive valve incompetence and inversely related to coronary artery disease.
onclusion: Optimal 15-year durability can be expected in male patients 60 years
nd older who have undergone aortic valve replacement and in male patients 65
ears and older who have undergone mitral valve replacement, extending safely the
ge limits for the use of this valve.
he aim of this multicenter study was to assess the long-term performance of
isolated Hancock II aortic valve replacement (AVR) and mitral valve re-
placement (MVR) and compare it with similar North American follow-up1,2
nd to formulate recommendations for the use of this prosthesis.
atients and Methods
atients
rom 1983 through 2002, 1274 patients received 1293 isolated aortic (n 809) or mitral (n
84) Hancock II prostheses at one of 3 institutions: the Treviso hospital, the University of
vascular Surgery ● September 2006
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CDadova, or the Venezia hospital. Age, sex, and the distribution of
everal covariates are summarized in Table 1. Treviso contributed
84 records, Padova contributed 180, and Venezia contributed 129.
ollow-up
ollow-up was through mail or by telephone interview and was
losed on January 1, 2003; it was 97% complete and included 8520
atient-years (median, 12 years). Aortic follow-up was 5193 years,
nd mitral follow-up was 3327 years. Data analysis is reported at
5 years, with 27 mitral and 26 aortic valves at risk.
perative Technique
imilar techniques were used in all 3 institutions with buttressed
utures. Prosthetic size was according to the patients’ body size,
nd therefore the smallest aortic prosthesis inserted was 21 mm,
nd the smallest mitral prosthesis was 27 mm. Coronary artery
ypass grafting was performed in patients with coronary artery
isease of 70% or greater.
utcomes
he primary outcomes were all-cause mortality and structural
alve deterioration (SVD), which was defined as every clinical
orsening caused by an intrinsic disease of the prosthesis (stenosis
r incompetence) exclusive of infection or thrombosis and ob-
erved at reoperation, autopsy, or echocardiography. Additional
utcomes were analyzed according to the guidelines of the Amer-
can Association for Thoracic Surgery3 and included valve-related
ortality; mortality and morbidity; permanent or transitory em-
olic events and hemorrhagic events requiring hospitalization
lood transfusion, or both; prosthetic endocarditis; prosthetic throm-
osis; and repeat AVR or MVR.
tatistical Analyses
atients were censored when the valve was replaced, unless they
ere dead at the time of reoperation. The STATA statistical
ackage was used (STATA Corp).
Univariate analysis. Prognostic variables were evaluated by
sing t tests and the Fisher exact test, and timed events were
valuated with the Kaplan-Meier method. Linearized rates were
sed for practical advantage unless clearly inappropriate.4 Simul-
aneous decrement analysis of survival with the original prosthesis
as performed according to the method of Anderson5 by subtract-
ng the cumulative incidences of death and SVD.
Multivariable analysis. Variables tested for their association
ith outcome were valve position (mitral and aortic), demograph-
cs (age and sex), valve pathology (insufficiency, mixed lesion,
tenosis, active endocarditis, healed endocarditis, rheumatic, de-
enerative, ischemic, prosthetic pathology, and other pathology),
Abbreviations and Acronyms
AVR  aortic valve replacement
MVR mitral valve replacement
NYHA New York Heart Association
SVD  structural valve deteriorationreceding SVD event, preceding Hancock valve insertion, clinical t
The Journal of Thoracicactors (New York Heart Association [NYHA] class, atrial fibril-
ation, pacemaker, operative date, ascending aorta replacement,
oronary artery bypass grafting, left internal thoracic artery use,
mergency operation, operative center), and associated risk factors
hypertension, chronic renal failure, diabetes, previous cardiac sur-
ery, coronary artery disease, critical coronary artery disease). Vari-
bles affecting late survival were evaluated by means of the Cox
emiparametric model, and variables affecting SVD were evaluated
y means of the Weibull parametric model. Variable choice, by
eans of stepwise backward and forward algorithm (P to enter 
19, P to retain  .2), was supported by bootstrap analysis, with
000 repetitions of randomly selected samples with replacement.
esults
hirty-day Mortality
here were 44 early deaths after AVR (5.5%; 95% confi-
ence interval, 4%-7.2%) and 32 after MVR (6.6%; 95%
onfidence interval, 4.5%-9.2%).
atient Survival
ortic mortality occurred in 280 patients, and mitral mor-
ality in 197 patients. Actuarial survival at 5, 10, and 15
ears was 79.9% 1.5%, 59% 2.2%, and 39.7% 3.5%
n the AVR group and 77.4%  2%, 56.7%  2.8%, and
9%  3.5% in the MVR group. The cause of late death
as unknown in 17 mitral and 27 aortic patients.
alve-related Deaths
alve-related deaths occurred in 112 patients in the AVR
roup and 82 patients in the MVR group. Fifteen-year
reedom from valve-related mortality was 71%  3% in the
VR group and 68%  3.8% in the MVR group (P  .33,
igure E1), and the linearized rates were 2.2% versus 2.5%
er patient-year for AVR and MVR, respectively.
udden or Unexplained Death
udden or unexplained death occurred in 18 patients in the
VR group and in 12 patients in the MVR group. Fifteen-year
ctuarial freedom was 95% 1% in both the aortic and mitral
osition, with a linearized rate of 0.35% per patient-year.
reedom From Valve-related Mortality and Morbidity
ctuarial freedom from valve-related mortality and morbid-
ty is summarized in Table 2. The linearized rates were
.7% per patient-year and 5.2% per patient-year in the AVR
nd MVR groups, respectively (P  .008, Figure E2).
ardiac death was the most frequent cause of death and
ccounted for 169 (60%) deaths in the AVR group and 143
73%) deaths in the MVR group; 109 (39%) deaths in the
VR group and 54 (28%) deaths in the MVR group were
nrelated to the cardiovascular system.
ultivariate Survival Analysis
ootstrap of the multivariable Cox analysis of survival iden-ified 100% of the time (bootstrap drawings) the incremental
and Cardiovascular Surgery ● Volume 132, Number 3 603
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A
CDisk of older age, with a hazard ratio of 1.5 every decade of age
ncrement (Table E1). NYHA class was selected in 94% of the
ime. The NYHA class III had a hazard ratio of 1.4 compared
ith NYHA class I and II, and class IV had a hazard ratio of
.8 and 2.1 if cardiogenic shock was also present. Male sex
as selected out 99% of the time (bootstrap drawings), with a
azard ratio of 1.7; coronary artery disease was selected out
9% of the time (bootstrap drawings), with a hazard ratio of
.3; and mitral position was selected out 59% of the time
bootstrap drawings), with a hazard ratio of 1.35.
omplications
Embolism. There were 123 embolic episodes, 67 in the
ABLE 1. Covariates
Hancoc
n  8
Male sex 605
Female sex 204
Age, y 68.
NYHA class
I 32
II 354
III 298
IV 107
Cardiogenic shock (NYHA class V) 18
Endocarditis 28
Diabetes 35
Hypertension 75
Chronic renal failure 27
Emergency procedure 34
Previous cardiac surgery 67
Previous Hancock valve 16
Previous SVD episode 11
Valve pathology
Rheumatic 101
Degenerative 291
Prosthetic pathology 55
Stenosis 357
Regurgitation 221
Moderate stenosis and incompetence 245
Atrial fibrillation or flutter 81
CAD 256
CABG 238
LITA graft 165
Ascending aorta replacement 110
Crossclamp time (min) 8
Cardiopulmonary bypass time (min) 11
Operative era
2000-2002 123
1990-2000 517
1983-1989 169
YHA, New York Heart Association; SVD, structural valve deterioration; C
nternal thoracic artery.VR group and 56 in the MVR group. The linearized rate A
04 The Journal of Thoracic and Cardiovascular Surgery ● Septeas 1.3% per patient-year versus 1.8% per patient-year
P  .11, Figure E3). Fifteen-year freedom from embolism
s summarized in Table 2. Embolism caused 16 mitral
eaths (13 cerebral, 2 bowel infarction, and 1 peripheral
mbolism) and 22 aortic deaths (20 cerebral, 1 embolism of
he left main coronary artery, and 1 peripheral embolism).
ermanent neural deficit is recorded in 27 mitral and 15
ortic cases. Most (55%) embolic episodes occurred in
atients receiving anticoagulation therapy.
Thrombosis. There were 4 cases (Table 2) of thrombo-
is. One patient in the AVR group had an early thrombosis
ith occlusion of the left coronary ostium 5 days after the
peration and died. The second and third patients in the
ortic,
.3%)
Hancock II mitral,
n  484 (49.7%) P value
) 198 (25%) .0001
) 286 (58%) .0001
.0 65.8 8.6 .0001
4 (1%)
) 152 (31%) 0.8
) 238 (49%)
) 76 (16%)
14 (3%) .003
20 (4%) .5
18 (4%) .6
21 (4%) .001
16 (3%) 1.0
31 (6%) .08
93 (19%) .0001
34 (7%) .0001
27 (5%) .0001
) 110 (23%) .0001
) 106 (22%) .0001
64 (13%) .0001
) 48 (10%) .0001
) 273 (56%) .0001
) 136 (28%) .4
) 261 (54%) .0001
) 87 (18%) .0001
) 79 (16%) .0001
) 53 (11%) .0001
%) 0 .0001
0 66 24 .0001
1 101 38 .0001
) 48 (10%)
) 268 (55%)
) 168 (35%) .0001
oronary artery disease; CABG, coronary artery bypass grafting; LITA, leftk II a
09 (50
(75%
(42%
4 8
(4%)
(44%
(37%
(13%
(2%)
(3%)
(4%)
(9%)
(3%)
(4%)
(8%)
(2%)
(1%)
(12%
(36%
(7%)
(44%
(37%
(30%
(10%
(32%
(29%
(20%
(13.6
7 3
3 4
(15%
(64%
(21%
AD, cVR group underwent reoperation 4 years after the initial
mber 2006
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CDperation, and the fourth patient, who was thrombosed at 7
ears, was treated medically and died.
Hemorrhage. Patients in the MVR group had 26 hem-
rrhagic events versus 25 events in patients in the AVR
roup, resulting in a higher hemorrhage rate 0.8% versus
.5% per patient-year (P  .06, Figure E4). Fifteen-year
reedom is reported in Table 2. Mitral-related hemorrhage
as fatal in 11 (37%) patients, whereas aortic-related hem-
rrhage was fatal in 14 (56%) patients. Most hemorrhagic
pisodes (83%) occurred in patients receiving anticoagulant
reatment. The operative age of patients with hemorrhage
as similar for the MVR (60  14 years) and AVR (58 
3 years) groups (P  .18).
Endocarditis. There were 14 mitral and 23 aortic endo-
arditis episodes. Six mitral and 4 aortic episodes occurred
ithin the first postoperative year. The median interval was
.7 years. The linearized event rate for endocarditis was
.4% and 0.42% per patient-year for the AVR and MVR
roups (P  .94), respectively (Figure E5). Fifteen-year
reedom from endocarditis is summarized in Table 2. En-
ocarditis was the cause of 7 deaths in the MVR group and
3 deaths in the AVR group.
Dehiscence. There were 8 cases of late dehiscence, all
f which were mild except for 3 that were caused by
ndocarditis.
Reoperation. Eighty patients, 42 in the MVR group and
8 in the AVR group, required reoperation. The cause was
VD in 51 cases (19 in the AVR and 32 in the MVR
ABLE 2. Actuarial freedom from stated events
ollow-up (y)
Aortic
5 10
RD (patients at risk) 91.3% 1.0% (461)* 81.3% 1.9% (181) 70.
RMM (patients at risk) 85.2% 1.3% (434) 71.2% 2.2% (166) 51.
mbolism (patients at
risk)
94.2%  1.0% (442) 87.9% 1.6% (170) 81.
emorrhage (patients
at risk)
97.4%  0.6% (454) 95.8% 0.9% (177) 95.
ndocarditis (patients
at risk)
97.1%  0.7% (457) 95.8% 0.9% (181) 95.
hrombosis (patients
at risk)
99.5%  0.3% (460) 99.5% 0.3% (181) 99.
VD (patients at risk) 100.0% (461) 97.0% 0.1% (180) 84.
VD if age 60 y
(patients at risk)
100.0% (404) 98.1%  1.0% (151) 93.
VD if age 65 y
(patients at risk)
100.0% (330) 97.6%  1.3% (114) 94.
eoperation (patients
at risk)
97.5%  0.7% (460) 93.6% 1.3% (180) 82.
eoperation if age 60 y
(patients at risk)
94%  2.0% (58) 85% 5.0% (29) 55.
eoperation if age 60 y
(patients at risk)
98%  0.63% (402) 95% 1.2% (151) 90.
RD, Valve-related death; VRMM, valve-related mortality and morbidity; Sroups). The second most common cause was endocarditis 1
The Journal of Thoracicn 21 patients (12 in the AVR and 9 in the MVR groups).
wo patients in the AVR group underwent reoperations
or valve thrombosis, and 6 patients underwent reopera-
ions for miscellaneous reasons, including 1 heart transplan-
ation, 3 new valve involvements, 1 aortic aneurysm, and 1
ortic pseudoaneurysm. Patients undergoing reoperation
ere younger at the time of the original operation than those
ot undergoing reoperation (58  1.14 versus 68  0.2
ears, P  .0001). Fifteen-year actuarial freedom is re-
orded in Table 2 for all patients and according to operative
ge. Actual freedom from reoperation is summarized in
able 3, according to operative age.
SVD. SVD occurred in 57 patients, 21 in the AVR group
nd 36 in the MVR group. The prevalence of SVD was
.8% in patients 60 years and older in the MVR group
ersus 21% in younger patients and 1.1% in patients 60
ears and older in the AVR group versus 15% in younger
atients. Six (10.5%) patients had a prior Hancock Standard
alve, which was removed for deterioration. The median
nterval for diagnosis or reoperation was 12 years (range,
-19 years), 11 years for aortic valves and 13 years for
itral valves (P  .15). All but 1 patient in the AVR group
nd 3 patients in the MVR group underwent reoperation.
ctuarial freedom from SVD is recorded in Table 2 and
igure 1 and stratified by age 60 to 65 or 65 or more years
n Figure E6. Actual 5-, 10-, and 15-year freedom from
ortic valve SVD was 100%, 98  0.7%, and 92  1.9%,
nd freedom from mitral valve SVD was 100%, 95.6 
Mitral
5 5 10 15
3.1% (26) 89.7% 1.5% (304) 78.1% 2.5% (115) 67.7% 3.8% (27)
3.6% (26) 82.7% 1.8% (281) 62.6% 3.0% (95) 36.2% 4.4% (21)
2.9% (26) 92.7% 1.3% (286) 85.3% 2.2% (104) 71.8% 4.7% (24)
1.1% (26) 96.4% 1.0% (298) 91.7% 1.8% (109) 89.2% 2.4% (24)
1.2% (26) 97.8% 0.7% (303) 95.3% 1.5% (115) 94.4% 1.7% (27)
0.3% (26) 100.0% (302) 99.5%  0.5% (115) 99.5% 0.5% (27)
0.4% (26) 100.0% (304) 93.2%  0.2% (115) 70.8% 0.5% (27)
2.5% (19) 100.0% (230) 95.9%  1.9% (71) 72.0% 7.4% (11)
2.6% (12) 100.0% (172) 94.9%  2.7% (41) 75.6% 9.2% (4)
3.7% (26) 98.0% 0.7% (303) 91.8% 2.1% (115) 71.0% 5.0% (27)
10% (7) 96.5% 2.0% (75) 85.5% 4.6% (45) 64.7% 7.4% (16)
2.6% (19) 98.3% 0.75% (228) 95%  1.8% (71) 73.5%  7.3% (11)
tructural valve deterioration. *Parentheses indicate patients at risk.1
8%
6%
2%
2%
0%
5%
7%
3%
2%
3%
8% 
4% .3%, and 85  2.6%, respectively (Table 3).
and Cardiovascular Surgery ● Volume 132, Number 3 605
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A
CDBootstrapped multivariable Weibull analysis of SVD de-
erminants (Table E2) identified 97% of the time (bootstrap
rawings) older age as a powerful decremental risk factor
or this complication, with an overall hazard reduction of
2% for every 10-year age increment. Given the exponential
elationship of SVD and age, the hazard ratio was 1.5 for
atients younger than 60 years of age, 0.7 for patients 60 to
0 years of age, and 0.2 for patients 70 to 80 years of age.
oronary artery disease was also a possible decremental
isk factor identified 60% of the time with a hazard reduc-
ion of 75%. Incompetence of the natural valve was identi-
ed in 65% of the random samples as a possible incremental
isk factor for SVD with a hazard ratio of 1.8. In aortic
ncompetence SVD prevalence was 6% versus 2% in ste-
osis, and median valve size was 25 mm versus 23 mm,
espectively. There was a trend toward longer median du-
ability of the aortic valve (19  3.5 years vs 18  2.5
ears, P  .23), but valve position was bootstrapped less
ABLE 3. Actual freedom from structural valve deteriorati
Aortic
ollow-up (y) 5 10
VD 100.0% (461)* 98.0% 0.7% (180) 91.9%
VD if age 60 y 100.0% (57) 92.7% 3.5% (29) 70.4%
VD if age 60 y 100.0% (403) 98.8% 0.6% (151) 96.5%
VD if age 65 100.0% (333) 98.5% 0.7% (114) 96.9%
eoperation 97.9% 0.5% (459) 95.3%  4.7% (179) 89.6%
eoperation if
age 60 y
94.5%  2.6% (57) 87.4%  4.2% (29) 68.1%
eoperation if
age 60 y
98.3%  0.5% (402) 96.4%  0.8% (150) 94.1%
VD, Structural valve deterioration. *Parentheses indicate patients at risk06 The Journal of Thoracic and Cardiovascular Surgery ● Septehan 50% of the time. SVD freedom according to age and
alve position is shown in Figure 2.
imultaneous Decremental Analysis
t 15 years, this analysis shows that patients 60 years and
lder in the MVR group had an actual probability of being
live with the original prosthesis of 28%, a 60% probability
f being dead, and a 12% probability of SVD (Figure 3). In
atients 60 years and older in the AVR group, the analysis
hows an actual probability of being alive with the original
rosthesis of 33.5%, a 63% probability of being dead, and a
.5% probability of SVD (Figure 4).
linical Status
ive hundred fifty-one (69%) patients are in NYHA class I,
nd 201 (25%) are in NYHA class II. Sixty percent of the
atients were off anticoagulants. Sinus rhythm was present
n 141 (49%) patients in the MVR group and in 419 (91%)
nd reoperation
Mitral
5 10 15
(26) 100.0% (304) 95.6%  2.6% (115) 85.1%  2.6% (27)
(7) 100.0% (74) 89.8%  3.6% (44) 77.5%  5.3% (16)
(19) 100.0% (389) 97.5%  1.1% (71) 87.8%  3.2% (11)
(12) 100.0% (305) 97.0%  1.6% (41) 89.5%  3.8% (4)
(26) 98.3%  0.6% (301) 94.3%  1.3% (115) 84.5%  2.6% (27)
(7) 96.8%  1.8% (74) 86.6%  3.9% (44) 74.3%  5.4% (16)
(19) 98.6%  0.6% (227) 96.6%  1.1% (71) 88.0%  3.1% (11)
Figure 1. Actuarial freedom from SVD according
to valve position. SVD, structural valve deterio-
ration; CL, confidence limit.on a
15
 8.1%
 7.5%
 1.3%
 1.4%
 1.9%
 7.3%
 1.4%mber 2006
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CDatients in the AVR group; 4 patients in the MVR group and
5 in the AVR group required a pacemaker insertion.
iscussion
econd-generation tissue valves have been engineered to
nhance their durability. Results of multicenter investiga-
ions with reasonable groups at risk after a follow-up of 15
o 20 years are desirable to support a policy of prosthetic
alve choice.6 At 15 years, we compared 26 aortic and 27
itral second-generation Hancock II valves with 18 aortic
nd 9 mitral valves reported in 2001 by David and col-
eagues2 and with 43 aortic and 8 mitral valves reported at
igure 2. Predicted probability of freedom from SVD according to
perative age and to the mean of the covariates in the mitral and
ortic position from the Weibull multivariable model. SVD, struc-
ural valve deterioration.
igure 3. Simultaneous decremental analysis of the events of
VD, death, and survival with the original prosthesis based on
heir cumulated incidence for the Mitral Hancock II valve in
atients with an operative age of 60 years or greater. SVD,structural valve deterioration.
The Journal of Thoracic4 years by the Medtronic Multi-Center Clinical Investiga-
ion of 8 US hospitals.1 Indication for use of this valve were
imilar, and ages of our patients were close to those reported
y David and colleagues2 and by the Medtronic study,1
ermitting unconfounded comparisons. The overall survival
ate at 5 and 10 years was similar to that in the series by
avid and colleagues2 and Medtronic.1 At 15 years, sur-
ival was 33% in the Medtronic study,1 40% in the present
tudy, and 47% in the study by David and colleagues.2 In
he mitral series our results were generally better than those
eported in the studies by David and colleagues2 and
edtronic1 (39% vs 30% vs 25%), although this was likely
ue to differences in clinical presentation and NYHA class
revalence. Operative mortality is unrelated to prosthetic
evices, with the exception of the incremental risk of small
ortic prostheses.7 In this respect a 21-mm size was used in
nly 2.2% of our patients compared with in 19.9% of
atients in the Medtronic series1 and in 7% of patients in the
eries by David and colleagues,2 and we did not use the
5-mm valve mitral prostheses. Long-term outcome after
rosthetic valve replacement8 is affected by prosthetic com-
lications, which, at 15 years, have been few and similar in
he 3 series. A single exception is the 15-year freedom from
alve-related deaths: in AVR this estimate was 92% in the
eries by David and colleagues2 versus 71% in our series
nd 72% in the Medtronic series,1 and in MVR this was
6% versus 68% versus 63%, respectively. The difference is
ue to the bias from inclusion of unknown causes of death,
hich were only 4 in the series by David and colleagues.2
reedom from embolism in AVR ranged from 83% to 78%
nd in MVR from 87% to 67%. Freedom from hemorrhage
as 90% in the MVR group and 95% in the AVR group,
igure 4. Simultaneous decremental analysis of the events of
VD, death, and survival with the original prosthesis based on
heir cumulated incidence for the Aortic Hancock II valve in
atients with an operative age of 60 years or greater. SVD,
tructural valve deterioration.
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A
CDhich is similar to results seen in the Medtronic series.1
reedom from endocarditis was close to 95% in both AVR
nd MVR, which is similar to the rates observed in both of
he other series. Endocarditis occurred mostly in the first
ostoperative year and randomly thereafter. Primary valve
hrombosis in 4 valves was mostly caused by previous
ndocarditis. The Medtronic series1 reported 3 cases of
ortic valve thrombosis, and there were none in the series by
avid and colleagues.2 Composite end points exaggerate
ifferences in data reporting, and therefore overall freedom
rom valve-related mortality and morbidity compared with
hat seen in the series by David and colleagues2 was 52%
ersus 59% in patients in the AVR group and 36% versus
8% in patients in the MVR group.
Valve position was not significant in our multivariable
nalysis of durability, and durability estimates converge in
lder patients (Figure 2). This is similar to the finding of the
ame grade of calcification in pairs of aortic and mitral
ioprostheses simultaneously explanted from the same pa-
ient in the study by Bortolotti and associates.9 Our dura-
ility estimate (including patients not undergoing reopera-
ion) for MVR in patients 60 years and older shows 15-year
reedom of 88%, which is similar to the 89% freedom
eported by David and colleagues.2
In AVR our data show 96.5% freedom from SVD
ersus 94% and 100% freedom observed by Medtronic1 and
avid and colleagues,2 respectively. These results are sim-
lar to those with another second-generation porcine valve,
he Carpentier-Edwards SAV, for which Jamieson and co-
orkers10 reported 95% freedom from SVD in 100 patients
lder than 60 years. At 10-year follow-up, our results com-
are favorably with the Biocor valve results recently pub-
ished by Myken.11 In fact, this large series of a recently US
ood and Drug Administration (FDA)–approved valve has
nly 5 patients who underwent AVR and no patients who
nderwent MVR who are older than 60 years of age and
ho are at risk at 15 years. It has been recently suggested by
ahimtoola6 that “the pericardial aortic valve may be the
ioprosthesis of choice in older people.” Indeed, Gao and
ssociates12 recently reported that the Perimount pericardial
ortic valve was superior to the Edwards porcine valve.
owever, in these instances the comparisons are with first-
eneration porcine valves and not the second-generation
ancock II valve reported here. Gao and associates’ Peri-
ount durability of 99% freedom from explants for SVD at
0 years, with 6 valves at risk, is similar to our 98.7%
reedom from all SVD, with 180 valves at risk. The analysis
y Banbury and coworkers13 of the 267 Perimount aortic
alves with comparable age (65 years) and mean follow-up
12 years) reveals a freedom of explants for SVD of 77% at
5 years versus 92.5%, 90%, and 97% freedom from SVD
or the Hancock II valve reported by Medtronic1 and David
nd colleagues2 and in the present study, respectively. Our
08 The Journal of Thoracic and Cardiovascular Surgery ● SepteVR freedom from SVD results also compare favorably
ith those reported for the Perimount mitral valve: March-
nd and colleagues14 note a freedom from SVD of 66.3% at
4 years with 11 patients at risk versus our observation of
0.8% at 15 years with 27 patients at risk.
Jamieson and Madani15 commented that durability at 20
ears will be the important milestone. Although 5% of our
alves have been followed beyond 16 years, it is difficult for
s to make accurate projections up to 20 years. Nonetheless,
ccording to the 2002 Italian life tables,16 the life expect-
ncy of a 60-year-old male is 20.8 years (25.2 years for a
oman) versus a 19-year median durability of the aortic and
8-year median durability of the mitral Hancock II valve.
herefore given the AVR data observed here and the sig-
ificantly reduced hemorrhage17-19 and thromboembolic
isk17 provided by the bioprosthesis, the data encourage use
f this valve in males 60 years and older, particularly if
oronary artery disease is also present. Observation of ac-
umulated mitral SVD probability higher than 10% in pa-
ients 65 years and older and the prevalence of female sex
ith a 5-year longer expected survival balanced against
he good freedom from all valve complications of the St
ude Medical mechanical valve reported by Khan and co-
orkers20 might warrant a more prudent attitude for valve
hoice in MVR. The trend to provide total treatment for
itral valve disease, including atrial fibrillation ablation and
eft appendage removal, will require reassessing the pros
nd cons of biologic versus mechanical substitutes in this
etting.
In conclusion, our results, with reasonable groups at risk,
ompare favorably with those of other reports and other
ioprostheses and confirm the excellent durability of the
ancock II valve, particularly in patients 60 years and older
ndergoing AVR and patients 65 years and older undergo-
ng MVR.
Limitations of the study include center bias (76% of the
perations at a single center) and recall bias caused by ad
oc follow-up. A biased estimate of valve-related death and
alve-related mortality and morbidity is also possible due to
4 (11%) untraced cause of late deaths.
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CDFigure E1. Freedom from valve-related death according to mitral valve replacement or aortic valve replacement.
Figure E2. Freedom from valve-related mortality and morbidity according to mitral valve replacement or aortic
valve replacement. VRMM, valve-related mortality and morbidity.
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CDABLE E1. Cox multivariable analysis of late survival
ariables Bootstrap* HR SE P > |z| 95% CI
itral prosthesis 59% 1.35 0.155 .009 1.08-1.69
ogarithm of age (y) 100% 11.11 4.958 .001 4.64-26.64
ale sex 99% 1.68 0.196 .001 1.34-2.12
revious operation 74% 1.46 0.200 .005 1.12-1.91
oronary artery disease 69% 1.33 0.157 .015 1.05-1.67
YHA class 94% 1.352 0.0837 .001 1.20-1.53
R, Hazard ratio; SE, standard error; CI, confidence interval; NYHA, New York Heart Association. *Percentage of variable inclusion in 1000 repetitions ofFigure E3. Freedom from embolism according to mitral valve replacement or aortic valve replacement.
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CDFigure E4. Freedom from hemorrhage according to mitral valve replacement or aortic valve replacement.Figure E5. Freedom from endocarditis according to mitral valve replacement or aortic valve replacement.
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A
CDFigure E6. Actuarial freedom from structural valve deterioration (SVD) according to age between 60 and 65 years
or 65 or greater years.
ABLE E2. Weibull multivariable analysis of the event SVD
ariables Bootstrap* HR SE P > |z| 95% CI
xponential of age (y) 97% 0.36 0.100 .000 0.21-0.63
atural valve incompetence 65% 1.76 0.477 .037 1.04-2.99
oronary artery disease 60% 0.25 0.180 .055 0.059-1.03
n p 100% 1.43 0.094 .000 1.24-1.61
itral position 47% 1.44 0.409 .20 0.83-2.52
R, Hazard ratio; SE, standard error; CI, confidence interval; ln p, natural logarithm of the shape parameter. *Percentage of variable inclusion in 1000
epetitions of multivariable backward stepwise model (P to remain  .20, P to enter  .19).
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